HRP20190842T1 - Kristalni oblici 2-((4s)-6-(4-hlorofenil)-1-metil-4h-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamida - Google Patents
Kristalni oblici 2-((4s)-6-(4-hlorofenil)-1-metil-4h-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamida Download PDFInfo
- Publication number
- HRP20190842T1 HRP20190842T1 HRP20190842TT HRP20190842T HRP20190842T1 HR P20190842 T1 HRP20190842 T1 HR P20190842T1 HR P20190842T T HRP20190842T T HR P20190842TT HR P20190842 T HRP20190842 T HR P20190842T HR P20190842 T1 HRP20190842 T1 HR P20190842T1
- Authority
- HR
- Croatia
- Prior art keywords
- water
- isoxazolo
- azepin
- chlorophenyl
- benzo
- Prior art date
Links
- GCWIQUVXWZWCLE-INIZCTEOSA-N pelabresib Chemical compound N([C@@H](CC(N)=O)C=1ON=C(C=1C1=CC=CC=C11)C)=C1C1=CC=C(Cl)C=C1 GCWIQUVXWZWCLE-INIZCTEOSA-N 0.000 title claims 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 13
- 150000004682 monohydrates Chemical class 0.000 claims 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- 239000013078 crystal Substances 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000003960 organic solvent Substances 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (13)
1. Kristalni monohidrat oblika A 2-((4S)-6-(4-hlorofenil)-1-metil-4H-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamida, pri čemu je kristalni oblik naznačen time što se najmanje tri najviše vrijednosti rendgenske difrakcije praha dostiže pod 2Θkutevima odabranim od 4,73°, 18,09°, 18,48°, 18,80°, 19,70°, i 25,17°.
2. Kristalni monohidrat oblika A sukladno patentnom zahtjevu 1, pri čemu je taj kristalni oblik naznačen time što se najmanje četiri najviših vrijednosti rendgenske difrakcije praha dostiže pod 2Θ kutevima odabranim od 4,73°, 18,.09°, 18,48°, 18,80°, 19,70°, i 25,17°.
3. Kristalni monohidrat oblika A sukladno patentnom zahtjevu 1 ili 2, pri čemu je taj kristalni oblik naznačen time što se najmanje pet najviših vrijednosti rendgenske difrakcije praha dostiže pod 2Θ kutevima odabranim od 4,73°, 18,09°, 18,48°, 18,80°, 19,70°, i 25,17°.
4. Kristalni monohidrat oblika A sukladno bilo kojem od patentnih zahtjeva 1 do 3, pri čemu je, taj kristalni oblik naznačen time što se najviše vrijednosti rendgenske difrakcije praha dostižu pod 2Θkutevima 4,73°, 18,09°, 18,48°, 18,80°, 19,70°, i 25,17°.
5. Kristalni monohidrat oblika A sukladno bilo kojem od patentnih zahtjeva 1 do 4, pri čemu je taj kristalni oblik naznačen time što se najviše vrijednosti rendgenske difrakcije praha dostižu pod 2Θ kutevima 4,73°, 9,42°, 12,91°, 18,09°, 18,48°, 18,80°, 19,70°, 21,42°, i 25,17°.
6. Kristalni monohidrat oblika A sukladno bilo kojem od patentnih zahtjeva 1 do 5, pri čemu je taj kristalni oblik naznačen time što se najviše vrijednosti rendgenske difrakcije praha dostižu pod 2Θ kutevima 4,73°, 8,11°, 9,42°, 12,91°, 14,10°, 14,97°, 18,09°, 18,48°, 18,80°, 19,70°, 21,42°, i 25,17°, 26,07°, i 26,53°.
7. Farmaceutski pripravak koji sadrži oblik kristalnog monohidrata sukladno bilo kojem od patentnih zahtjeva 1 do 6; i farmacutski prihvatljiv nosač ili otapalo.
8. Kristalni monohidrat oblika A 2-((4S)-6-(4-klorofenil)-1-metil-4H-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamida sukladno bilo kojem od patentnih zahtjeva radi liječenja proliferativnog poremećaja, bolesti upale, sepse, autoimunih bolesti, ili virusne infekcije.
9. Kristalni monohidrat oblika A 2-((4S)-6-(4-klorofenil)-1-metil-4H-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamida za uporabu sukladno patentnom zahtjevu 8, pri čemu je taj poremećaj karcinom.
10. Postupak dobivanja kristalnog monohidrata oblika A 2-((4S)-6-(4-klorofenil)-1-metil-4H-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamida, taj postupak obuhvaća:
stvaranje kristalnog monohidrata oblika A iz otopine koja sadrži amorfni 2-((4S)-6-(4-klorofenil)-1-metil-4H-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamid i vodu; ili iz mješavine koja sadrži amorfni 2-((4S)-6-(4-klorofenil)-1-metil-4H-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamid, i kombinaciju vode i organskog otapala.
11. Postupak sukladno patentnom zahtjevu 10, pri čemu se kombinacija vode i organskog otapala izabire od etanola/vode, izopropanola/vode, tetrahidrofurana/vode, acetona/vode, metanola/vode, i acetonitrila/vode.
12. Postupak sukladno patentnom zahtjevu 10 ili 11, pri čemu je kombinacija vode i organskog otapala etanol/voda.
13. Postupak sukladno bilo kojem od patentnih zahtjeva 10 do 12, pri čemu je kombinacija vode i organskog otapala u odnosu od 60:40 mješavine etanola/vode
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462014782P | 2014-06-20 | 2014-06-20 | |
EP15733597.7A EP3157928B1 (en) | 2014-06-20 | 2015-06-18 | Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
PCT/US2015/036347 WO2015195862A1 (en) | 2014-06-20 | 2015-06-18 | Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4s5-e]azepin-4-yl)acetamide |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20190842T1 true HRP20190842T1 (hr) | 2019-08-09 |
Family
ID=53499102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20190842TT HRP20190842T1 (hr) | 2014-06-20 | 2019-05-07 | Kristalni oblici 2-((4s)-6-(4-hlorofenil)-1-metil-4h-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamida |
Country Status (17)
Country | Link |
---|---|
US (1) | US9969747B2 (hr) |
EP (1) | EP3157928B1 (hr) |
JP (1) | JP6682522B2 (hr) |
CN (1) | CN106687463B (hr) |
CA (1) | CA2952830C (hr) |
CY (1) | CY1121997T1 (hr) |
DK (1) | DK3157928T3 (hr) |
ES (1) | ES2725928T3 (hr) |
HR (1) | HRP20190842T1 (hr) |
HU (1) | HUE043441T2 (hr) |
LT (1) | LT3157928T (hr) |
PL (1) | PL3157928T3 (hr) |
PT (1) | PT3157928T (hr) |
RS (1) | RS58730B1 (hr) |
SI (1) | SI3157928T1 (hr) |
TR (1) | TR201906788T4 (hr) |
WO (1) | WO2015195862A1 (hr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA038494B1 (ru) | 2013-03-15 | 2021-09-07 | Инсайт Холдингс Корпорейшн | Трициклические гетероциклы как ингибиторы белков бэт |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
SI3674302T1 (sl) | 2014-04-23 | 2023-07-31 | Incyte Holdings Corporation | 1h-pirolo(2,3-c)piridin-7(6h)-oni in pirazolo(3,4-c)piridin-7(6h)-oni kot zaviralci proteinov bet |
UA125476C2 (uk) | 2016-06-20 | 2022-03-23 | Інсайт Корпорейшн | Спосіб отримання 2,2,4-триметил-8-(6-метил-7-оксо-6,7-дигідро-1н-піроло[2,3-c]піридин-4-іл)-6-(метилсульфоніл)-2н-бензо[b][1,4]оксазин-3(4н)-ону і проміжних сполук |
CA3045855A1 (en) | 2016-11-10 | 2018-05-17 | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof |
EP3731842A1 (en) * | 2017-12-28 | 2020-11-04 | Constellation Pharmaceuticals, Inc. | Pharmacokinetic enhancement of ezh2 inhibitors through combination therapies |
WO2021091532A1 (en) | 2019-11-05 | 2021-05-14 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
CA3120973A1 (en) | 2018-11-27 | 2020-06-04 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
MX2021006205A (es) | 2018-11-27 | 2021-10-13 | Constellation Pharmaceuticals Inc | Metodos de tratamiento de trastornos mieloproliferativos. |
WO2021091535A1 (en) | 2019-11-05 | 2021-05-14 | Constellation Pharmaceuticals, Inc. | Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor |
WO2020256739A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
WO2020257644A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
MX2023001552A (es) | 2020-08-04 | 2023-05-03 | Constellation Pharmaceuticals Inc | 2-((4s)-6-(4-clorofenil)-1-metil-4h-benzo[c]isoxazolo[4,5-e]azepi n-4- il)acetamida para tratar trombocitemia. |
JP2024517472A (ja) | 2021-05-11 | 2024-04-22 | コンステレーション・ファーマシューティカルズ・インコーポレイテッド | 貧血を処置するためのペラブレシブの使用 |
WO2023147149A1 (en) * | 2022-01-31 | 2023-08-03 | Constellation Pharmaceuticals, Inc. | Anhydrous crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
Family Cites Families (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3523939A (en) | 1967-07-03 | 1970-08-11 | Hoffmann La Roche | 5-(2,6-disubstituted phenyl)-1,4-benzodiazepines and methods for their preparation |
CH498846A (de) | 1967-08-09 | 1970-11-15 | Hoffmann La Roche | Verfahren zur Herstellung von Benzodiazepin-Derivaten |
US3709898A (en) | 1971-02-09 | 1973-01-09 | Upjohn Co | Process for the production of triazolobenzodiazepines and intermediates |
US3781289A (en) | 1971-02-09 | 1973-12-25 | Upjohn Co | 7-chloro-1-methyl-5-phenyl-s-triazolo (4,3-a)quinolines |
US3681343A (en) | 1971-05-11 | 1972-08-01 | Upjohn Co | 6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines |
US3903103A (en) | 1971-09-15 | 1975-09-02 | Upjohn Co | 4-Amino-s-triazolo-{8 4,3-a{9 {8 1,4{9 benzodiazepine |
DE2242918A1 (de) | 1971-09-15 | 1973-03-22 | Upjohn Co | Neue 4-amino-s-triazolo eckige klammer auf 4,3-a eckige klammer zu eckige klammer auf 1,4 eckige klammer zu benzodiazepine |
US3886141A (en) | 1971-10-07 | 1975-05-27 | Hoffmann La Roche | Preparation of 5-pyridyl benzodiazepine utilizing hexamethylenetetramine |
BE795790A (fr) | 1972-02-22 | 1973-08-22 | Upjohn Co | Dibenzo-triazolo-azepine |
US4155904A (en) | 1973-02-08 | 1979-05-22 | Schering Corporation | Process for the preparation of 1,4-benzo-diazepines and 1,4-benzodiazepinones |
IE38931B1 (en) | 1973-03-09 | 1978-07-05 | Lipha | Triazolobenzodiazepines |
FR2220257A1 (en) | 1973-03-09 | 1974-10-04 | Lipha | 5,6-Dihydro-(4H)-s-triazolo-(4,3-a) (1,5)benzodiazepines - as antiinflam-matory and analgesic agents without tranquillising effects |
US3966736A (en) | 1975-04-07 | 1976-06-29 | The Upjohn Company | 2,9-Dihydro-3H-pyrido[3,2-c]-s-triazolo[4,3-a][1,5]-benzodiazepin-3-ones |
AT350056B (de) | 1975-11-04 | 1979-05-10 | Degussa | Verfahren zur herstellung von neuen pyrido- (2,3-f)-(1,4)-diazepinen, deren optischen isomeren und salzen |
DE2640599A1 (de) | 1976-09-09 | 1978-03-16 | Scherico Ltd | Verfahren zur herstellung von 1,4- benzodiazepinen |
CA1152066A (en) | 1980-02-08 | 1983-08-16 | Hoffmann-La Roche Limited | Benzodiazepine derivatives |
CA1163266A (en) | 1980-07-31 | 1984-03-06 | Albert E. Fischli | Benzodiazepine derivatives |
CA1157855A (en) | 1980-07-31 | 1983-11-29 | Albert E. Fischli | Benzodiazepine derivatives |
US4455307A (en) | 1982-01-04 | 1984-06-19 | The Upjohn Company | Antihypertensive use of triazolobenzodiazepines |
US5004741A (en) | 1984-06-26 | 1991-04-02 | Merck & Co., Inc. | Methods of antagonizing CCK or gastrin with benzodiazepine analogs |
US4820834A (en) | 1984-06-26 | 1989-04-11 | Merck & Co., Inc. | Benzodiazepine analogs |
US4663321A (en) | 1984-06-26 | 1987-05-05 | Merck & Co., Inc. | Triazolobenzodiazepines and pharmaceutical use |
ATE86256T1 (de) | 1987-05-28 | 1993-03-15 | Yoshitomi Pharmaceutical | Thieno(triazolo)diazepinverbindungen, und medizinische verwendung derselben. |
US4959361A (en) | 1987-12-18 | 1990-09-25 | Hoffmann-La Roche Inc. | Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists |
MC1999A1 (fr) | 1987-12-18 | 1990-01-26 | Hoffmann La Roche | Composes tricycliques |
WO1989005812A1 (en) | 1987-12-22 | 1989-06-29 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compounds and their medicinal use |
CA1324863C (en) | 1988-01-30 | 1993-11-30 | Minoru Moriwaki | Thienotriazolodiazepine compounds and pharmaceutical uses thereof |
CA1322367C (en) | 1988-05-17 | 1993-09-21 | Yoshitomi Pharmaceutical Industries Ltd. | Thienotriazolodiazepine compounds and pharmaceutical uses thereof |
US5221671A (en) | 1988-10-31 | 1993-06-22 | Eisai Co., Ltd. | Triazolo-1,4-diazepine derivatives and their use in pharmaceuticals |
US5382579A (en) | 1988-10-31 | 1995-01-17 | Eisai Co., Ltd. | Triazolo-1,4-diazepine derivatives and their use in pharmaceuticals |
FI95708C (fi) | 1988-10-31 | 1996-03-11 | Eisai Co Ltd | Analogiamenetelmä 1,4-diatsepiinijohdannaisen ja sen farmaseuttisesti sopivan suolan valmistamiseksi |
DE3936828A1 (de) | 1988-11-06 | 1990-05-10 | Boehringer Ingelheim Kg | Neue hetrazepine |
DE4006471A1 (de) | 1989-03-03 | 1990-09-06 | Boehringer Ingelheim Kg | Neue thienodiazepine |
YU133090A (sh) | 1989-07-12 | 1993-10-20 | Boehringer Ingelheim Kg. | Novi heteroazepini s paf-antaganostičnim učinkom in postopek za njihovo pripravo |
ATE119040T1 (de) | 1989-08-04 | 1995-03-15 | Merck Sharp & Dohme | Zentrale cholecystokinin-antagonisten zur behandlung von psychiatrischen krankheiten. |
US5175159A (en) | 1989-10-05 | 1992-12-29 | Merck & Co., Inc. | 3-substituted-1,4-benzodiazepines as oxytocin antagonists |
IL96613A0 (en) | 1989-12-18 | 1991-09-16 | Merck & Co Inc | Pharmaceutical compositions containing benzodiazepine analogs |
CA2032427A1 (en) | 1989-12-18 | 1991-06-19 | Mark G. Bock | Benzodiazepines analogs |
JP2971901B2 (ja) | 1990-03-15 | 1999-11-08 | エーザイ株式会社 | トリアゾロ―1,4―ジアゼピン系化合物 |
JP2971902B2 (ja) | 1990-03-15 | 1999-11-08 | エーザイ株式会社 | トリアゾロ―1,4―ジアゼピン系化合物 |
JP2959591B2 (ja) | 1990-05-23 | 1999-10-06 | 吉富製薬株式会社 | チエノトリアゾロジアゼピン化合物 |
WO1994006801A1 (en) | 1990-05-23 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
DE4027470A1 (de) | 1990-08-30 | 1992-03-05 | Boehringer Ingelheim Kg | Neue hetrazepinoide amide |
JP2959598B2 (ja) | 1990-10-12 | 1999-10-06 | 吉富製薬株式会社 | 光学活性なチエノトリアゾロジアゼピン化合物 |
US5206234A (en) | 1990-10-22 | 1993-04-27 | Merck & Co., Inc. | Benzolactam analogs as antagonists of cck |
CA2056809A1 (en) | 1990-12-07 | 1992-06-08 | Mark G. Bock | Benzodiazepine analogs |
DE4101146A1 (de) | 1991-01-16 | 1992-07-23 | Boehringer Ingelheim Kg | Neue in 6-position substituierte diazepine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
DE4107521A1 (de) | 1991-03-08 | 1992-09-10 | Boehringer Ingelheim Kg | Neue acylaminosubstituierte hetrazepine |
US5683998A (en) | 1991-04-23 | 1997-11-04 | Toray Industries, Inc. | Tricyclic triazolo derivatives, processes for producing the same and the uses of the same |
US5185331A (en) | 1991-05-14 | 1993-02-09 | Merck & Co., Inc. | Triazolobenzodiazepines |
EP0523846A3 (en) | 1991-06-14 | 1993-03-17 | Merck & Co. Inc. | 1,4-benzodiazepines with 5-membered heterocyclic rings |
GB9117852D0 (en) | 1991-08-19 | 1991-10-09 | Merck Sharp & Dohme | Therapeutic agents |
US5153191A (en) | 1991-08-20 | 1992-10-06 | Warner-Lambert Company | Cholecystokinin antagonists useful for treating depression |
DE4128581A1 (de) | 1991-08-28 | 1993-03-04 | Boehringer Ingelheim Kg | Verwendung von paf-antagonisten hetrazepinoider struktur zur behandlung der allergischen rhinitis |
ES2140396T3 (es) | 1991-09-30 | 2000-03-01 | Yoshitomi Pharmaceutical | Compuesto de tienodiazepina y su uso. |
JP3239364B2 (ja) | 1991-10-11 | 2001-12-17 | ウェルファイド株式会社 | 骨粗鬆症治療薬およびジアゼピン化合物 |
EP0656361B1 (en) | 1991-12-11 | 2000-04-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Autoimmune disease treating drug |
EP0617621A4 (en) | 1991-12-20 | 1995-04-05 | Merck Sharp & Dohme | CENTRAL CHOLECYSTOKININ ANTAGONISTS HAVING PHARMACEUTICAL EFFECTIVENESS. |
DE4200610A1 (de) | 1992-01-13 | 1993-07-15 | Boehringer Ingelheim Kg | Verwendung von paf-antagonisten zur behandlung der dysmenorrhea |
WO1993019052A1 (en) | 1992-03-24 | 1993-09-30 | Merck Sharp & Dohme Limited | 3-ureido substituted benzodiazepin-2-ones having cholecystokinin and/or gastrin antagonistic activity and their use in therapy |
DE4219659A1 (de) | 1992-06-16 | 1993-12-23 | Boehringer Ingelheim Kg | Die Verwendung von PAF-Antagonisten in Kombination mit Anticholinergika |
EP0661284A1 (en) | 1992-09-18 | 1995-07-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
US5302590A (en) | 1992-12-18 | 1994-04-12 | Hoffmann-La Roche Inc. | Compounds useful as dual antagonists of platelet activating factor and leukotriene D4 |
CA2159344A1 (en) | 1993-03-30 | 1994-10-13 | Minoru Moriwaki | Cell adhesion inhibitor and thienotriazolodiazepine compound |
US5843941A (en) | 1993-05-14 | 1998-12-01 | Genentech, Inc. | Ras farnesyl transferase inhibitors |
US5869483A (en) | 1993-07-29 | 1999-02-09 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5760031A (en) | 1993-07-29 | 1998-06-02 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5516774A (en) | 1993-07-29 | 1996-05-14 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
US5733905A (en) | 1993-07-29 | 1998-03-31 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
JP3633008B2 (ja) | 1993-11-15 | 2005-03-30 | 三菱ウェルファーマ株式会社 | チエノトリアゾロジアゼピン化合物 |
CA2176020A1 (en) | 1993-11-22 | 1995-06-01 | John J. Baldwin | Benzodiazepines |
ES2156933T3 (es) | 1993-12-28 | 2001-08-01 | Meiji Seika Co | Derivados triciclicos de benzazepina y benzotiazepina. |
US5739129A (en) | 1994-04-14 | 1998-04-14 | Glaxo Wellcome Inc. | CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines |
EP0755394A1 (en) | 1994-04-15 | 1997-01-29 | Glaxo Wellcome Inc. | A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds |
JP3264588B2 (ja) | 1994-08-23 | 2002-03-11 | 松下電器産業株式会社 | 電子地図データの生成装置 |
JP3264589B2 (ja) | 1994-09-07 | 2002-03-11 | 東芝機械株式会社 | 研磨装置 |
ATE214055T1 (de) | 1995-09-21 | 2002-03-15 | Inst Med Molecular Design Inc | Retinoid-potenzierende verbindungen |
CN1227555A (zh) | 1996-06-12 | 1999-09-01 | 日本烟草产业株式会社 | 细胞因子生成抑制剂、三氮䓬化合物及其中间体 |
CN1109037C (zh) | 1996-09-13 | 2003-05-21 | 三菱制药株式会社 | 噻吩并-***并二氮杂䓬化合物及其医药用途 |
KR20000069654A (ko) | 1996-12-23 | 2000-11-25 | 엘란 파마슈티칼스, 인크. | 시클로알킬, 락탐, 락톤 및 관련 화합물, 그의 약제학적 조성물및 그를 사용한 β-아밀로이드 펩티드의 방출 및(또는) 합성억제 방법 |
WO1998058930A1 (fr) | 1997-06-25 | 1998-12-30 | Nikken Chemicals Co., Ltd. | Composes de triazolo-1,4-diazepine et composition medicinale les contenant |
JP4204657B2 (ja) | 1997-12-05 | 2009-01-07 | 有限会社ケムフィズ | 糖尿病の予防・治療剤 |
JPH11228576A (ja) | 1997-12-10 | 1999-08-24 | Japan Tobacco Inc | アポトーシス抑制剤 |
FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
PE20000944A1 (es) | 1998-07-31 | 2000-09-20 | Lilly Co Eli | Derivados de sulfonamida |
JP2002525289A (ja) | 1998-09-01 | 2002-08-13 | イノジェネティックス・ナムローゼ・フェンノートシャップ | アネキシンに結合するベンゾジアゼピンおよびベンゾチアゼピン誘導体ならびにhsbsagペプチド、それらの組成物ならびに使用 |
AU2939000A (en) | 1999-03-12 | 2000-10-04 | Welfide Corporation | Preventive or therapeutic agents for inflammatory dermatoses |
FR2791980B1 (fr) | 1999-04-09 | 2001-07-06 | Sod Conseils Rech Applic | Pyrido-thieno-diazepines, leur procede de preparation, et les compositions pharmaceutiques les contenant |
US7160880B1 (en) | 1999-05-14 | 2007-01-09 | Cenes Limited | Short-acting benzodiazepines |
GB9911152D0 (en) | 1999-05-14 | 1999-07-14 | Glaxo Group Ltd | Short-acting benzodiazepines |
EP1244457B1 (en) | 1999-12-29 | 2004-10-27 | Glaxo Group Limited | Use of modulators of annexin for the manufacture of a medicament for the treatment and/or prevention of arthritis and arthritic diseases |
WO2001095912A1 (en) | 2000-06-16 | 2001-12-20 | Mitsubishi Pharma Corporation | COMPOSITIONS CONTROLLING RELEASE pH RANGE AND/OR SPEED |
WO2002098865A2 (fr) | 2001-06-07 | 2002-12-12 | Neuro3D | Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs |
US20050096322A1 (en) | 2002-03-01 | 2005-05-05 | Susumu Igarashi | Nitrogen-containing heterocyclic compound |
US20060128695A1 (en) | 2002-10-30 | 2006-06-15 | Neuro3D | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
DE10251927A1 (de) | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
KR100562489B1 (ko) | 2002-11-11 | 2006-03-21 | 삼성전자주식회사 | 셔터 타이밍 조절 가능한 로우 디코더를 갖는 이미지 센서 |
CA2510534C (en) | 2002-12-18 | 2011-09-20 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
US7119088B2 (en) | 2003-02-19 | 2006-10-10 | Pfizer Inc. | Triazole compounds useful in therapy |
CA2529558A1 (en) | 2003-07-01 | 2005-01-13 | Astellas Pharma Inc. | Agent inducing increase in bone mass |
WO2005099759A1 (ja) | 2004-04-16 | 2005-10-27 | Institute Of Medicinal Molecular Design. Inc. | 動脈硬化症の予防及び/又は治療のための医薬 |
WO2006038560A1 (ja) | 2004-10-05 | 2006-04-13 | Pioneer Corporation | オーディオラック |
TWI447120B (zh) | 2005-05-30 | 2014-08-01 | Mitsubishi Tanabe Pharma Corp | 噻吩并***并苯二氮呯化合物、其醫藥上之用途 |
US7947678B2 (en) | 2005-07-29 | 2011-05-24 | Merck Sharp & Dohme Corp. | Heterocyclic benzodiazepine CGRP receptor antagonists |
JP2009513644A (ja) | 2005-10-26 | 2009-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 治療組成物および方法 |
US20070105844A1 (en) | 2005-10-26 | 2007-05-10 | Regents Of The University Of Michigan | Therapeutic compositions and methods |
DE102005061840A1 (de) | 2005-12-23 | 2007-06-28 | Merck Patent Gmbh | Triazolderivate |
JPWO2008023847A1 (ja) | 2006-08-25 | 2010-01-14 | 日本ケミファ株式会社 | P2x4受容体拮抗剤 |
WO2008109856A2 (en) | 2007-03-07 | 2008-09-12 | Xenon Pharmaceuticals Inc. | Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions |
US20090111780A1 (en) | 2007-10-31 | 2009-04-30 | Everett Laboratories, Inc. | Compositions and methods for treatment of ear canal infection and inflammation |
ITFI20070288A1 (it) | 2007-12-21 | 2009-06-22 | A I L Firenze Sezione Autonoma | Inibitori delle deacetilasi istoniche |
US8476260B2 (en) | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
WO2009152589A1 (en) | 2008-06-17 | 2009-12-23 | Universidade Federal De Minas Gerais-Ufmg | Use of paf receptor for treating infections caused by flaviviridae |
JP5634990B2 (ja) | 2008-06-23 | 2014-12-03 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | タンパク質キナーゼ阻害剤 |
BRPI0914406A2 (pt) | 2008-10-30 | 2015-10-20 | Circomed Llc | composto, composição farmacêutica, e, método para aumentar os níveis no plasma de apo a1 em um mamífero |
WO2010121164A2 (en) | 2009-04-17 | 2010-10-21 | The Regents Of The University Of Michigan | 1,4-benzodiazepinone compounds and their use in treating cancer |
JP5768239B2 (ja) | 2009-05-07 | 2015-08-26 | 株式会社 PRISM BioLab | アルファへリックスミメティック及び関連の方法 |
US9062024B2 (en) | 2009-09-28 | 2015-06-23 | Nippon Soda Co., Ltd. | Nitrogen-containing heterocyclic compound and salt thereof, and a fungicide for agricultural and horticultural use |
GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
PT2722334E (pt) | 2009-11-05 | 2016-03-11 | Glaxosmithkline Llc | Inibidor do bromodomínio da benzodiazepina |
ES2539964T3 (es) | 2009-11-05 | 2015-07-07 | Glaxosmithkline Llc | Procedimiento novedoso |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
DK2496582T3 (en) | 2009-11-05 | 2016-03-21 | Glaxosmithkline Llc | Benzodiazepine-BROMDOMAeNEINHIBITOR. |
GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
EP2515914A4 (en) | 2009-12-23 | 2013-09-11 | Scripps Research Inst | BIOCONJUGATION OF TYROSINE BY EYE REACTIONS IN AQUEOUS MEDIA |
WO2011123678A2 (en) | 2010-03-31 | 2011-10-06 | Arqule, Inc. | Substituted benzo-pyrido-triazolo-diazepine compounds |
EP2571503B1 (en) | 2010-05-14 | 2015-01-07 | Dana-Farber Cancer Institute, Inc. | Compositions and their use in treating neoplasia, inflammatory disease and other disorders |
CA2799403C (en) | 2010-05-14 | 2020-01-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
JP6022442B2 (ja) | 2010-05-14 | 2016-11-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 男性用避妊組成物および使用方法 |
CN103119160B (zh) | 2010-05-14 | 2016-06-01 | 达那-法伯癌症研究所 | 用于调节代谢的组合物和方法 |
ES2526671T3 (es) | 2010-06-22 | 2015-01-14 | Glaxosmithkline Llc | Compuestos de benzotriazoldiazepina inhibidores de bromodominios |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
EP2705039B1 (en) | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
WO2013033420A1 (en) | 2011-08-30 | 2013-03-07 | Whitehead Institute For Biomedical Research | Methods of downregulating translocated oncogene expression using bromodomain inhibitors |
DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
RU2627702C2 (ru) | 2012-03-01 | 2017-08-10 | Эррэй Биофарма Инк. | Кристаллические формы 1-(3-трет-бутил-1-п-толил-1н-пиразол-5-ил)-3-(5-фтор-2-(1-(2-гидроксиэтил)-1н-индазол-5-илокси)бензил) мочевины гидрохлорида |
EP4190777A1 (en) | 2012-04-13 | 2023-06-07 | Epizyme, Inc. | Hbr salt form for ezh2 inhibition |
WO2013159006A1 (en) | 2012-04-20 | 2013-10-24 | Concert Pharmaceuticals, Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione |
EP2864336B1 (en) | 2012-06-06 | 2016-11-23 | Constellation Pharmaceuticals, Inc. | Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof |
-
2015
- 2015-06-18 US US15/319,995 patent/US9969747B2/en active Active
- 2015-06-18 TR TR2019/06788T patent/TR201906788T4/tr unknown
- 2015-06-18 CN CN201580033159.6A patent/CN106687463B/zh active Active
- 2015-06-18 PL PL15733597T patent/PL3157928T3/pl unknown
- 2015-06-18 RS RS20190562A patent/RS58730B1/sr unknown
- 2015-06-18 PT PT15733597T patent/PT3157928T/pt unknown
- 2015-06-18 LT LTEP15733597.7T patent/LT3157928T/lt unknown
- 2015-06-18 WO PCT/US2015/036347 patent/WO2015195862A1/en active Application Filing
- 2015-06-18 CA CA2952830A patent/CA2952830C/en active Active
- 2015-06-18 ES ES15733597T patent/ES2725928T3/es active Active
- 2015-06-18 DK DK15733597.7T patent/DK3157928T3/da active
- 2015-06-18 JP JP2017519447A patent/JP6682522B2/ja active Active
- 2015-06-18 EP EP15733597.7A patent/EP3157928B1/en active Active
- 2015-06-18 HU HUE15733597A patent/HUE043441T2/hu unknown
- 2015-06-18 SI SI201530737T patent/SI3157928T1/sl unknown
-
2019
- 2019-05-07 HR HRP20190842TT patent/HRP20190842T1/hr unknown
- 2019-05-13 CY CY20191100515T patent/CY1121997T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP2017519051A (ja) | 2017-07-13 |
EP3157928A1 (en) | 2017-04-26 |
DK3157928T3 (da) | 2019-05-20 |
SI3157928T1 (sl) | 2019-06-28 |
CA2952830C (en) | 2022-11-01 |
CN106687463B (zh) | 2019-04-09 |
HUE043441T2 (hu) | 2019-08-28 |
RS58730B1 (sr) | 2019-06-28 |
ES2725928T3 (es) | 2019-09-30 |
PL3157928T3 (pl) | 2019-07-31 |
US9969747B2 (en) | 2018-05-15 |
CN106687463A (zh) | 2017-05-17 |
JP6682522B2 (ja) | 2020-04-15 |
TR201906788T4 (tr) | 2019-05-21 |
CA2952830A1 (en) | 2015-12-23 |
CY1121997T1 (el) | 2020-10-14 |
WO2015195862A1 (en) | 2015-12-23 |
PT3157928T (pt) | 2019-05-30 |
EP3157928B1 (en) | 2019-02-13 |
LT3157928T (lt) | 2019-05-27 |
WO2015195862A8 (en) | 2016-01-28 |
US20170137434A1 (en) | 2017-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190842T1 (hr) | Kristalni oblici 2-((4s)-6-(4-hlorofenil)-1-metil-4h-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamida | |
CY1125110T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
EA201891099A1 (ru) | 7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7 | |
WO2013171729A3 (en) | Aryl and heteroaryl amide compounds as ror gamma t modulator | |
EA202091115A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
CL2016002310A1 (es) | Nuevos compuestos bicíclicos. | |
EA201790766A1 (ru) | Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
MX2017007748A (es) | Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk). | |
HRP20211834T1 (hr) | Kristalni čvrsti oblici 6-karboksi-2-(3,5-diklorfenil)benzoksazola | |
SG11201702498TA (en) | Synthesis of ordered microporous carbons by chemical vapor deposition | |
RU2020110358A (ru) | Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор- пиридин-3-ил]-пиразоло[1,5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы | |
AR101403A1 (es) | (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridin-3-carboxamida, su purificación para su uso como principio activo farmacéutico, un procedimiento para su preparación y su empleo en el tratamiento de enfermedades cardiovasculares | |
BR112015031619A2 (pt) | forma cristalina estável de cloridrato de tipiracil e método de cristalização para a mesma | |
RU2016146119A (ru) | Новый кристалл тетрациклического соединения | |
UY36737A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
HRP20210667T1 (hr) | Kristalni oblici antagonista androgenog receptora, postupak pripreme i njihova upotreba | |
RU2015140619A (ru) | Соль производного пиразолохинолина и ее кристалл | |
TW201613931A (en) | Form crystal of bisulfate of janus kinase (JAK) inhibitor and preparation method thereof | |
CL2016000387A1 (es) | Derivados de amida como antagonistas de ácido receptor lisofosfatidico | |
CY1122468T1 (el) | Κρυσταλλικη μορφη διθειικου αναστολεα κινασης jak και μια μεθοδος παρασκευης αυτου | |
WO2016103262A3 (en) | Crystal forms of apomorphine and uses thereof | |
HK1255313A1 (zh) | 含有培美曲塞或其藥學上可接受的鹽的穩定藥物組合物 | |
HRP20192237T1 (hr) | Derivati aminohidrotiazina kondenzirani s tetrahidrofuranom, korisni u liječenju alzheimerove bolesti | |
FR3023177B1 (fr) | Procede de preparation de co-cristaux par evaporation flash | |
HRP20190961T1 (hr) | Derivat tetrahidropirolo[3,4-d][1,3]tiazina kao inhibitor bace |